Heplisav-B market seen growing as adult vaccination demand rises

The Business Research Company says the Heplisav-B market could expand through 2035 as adult hepatitis B vaccination gains traction, especially for high-risk groups and workplace programs. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Heplisav-B is positioned to benefit from broader adult immunization efforts and rising demand for more convenient hepatitis B vaccination schedules. - The market opportunity extends beyond routine prevention, with demand tied to higher-risk adults, employer vaccination programs and chronic disease management. - The report frames hepatitis B prevention as a public health issue with commercial implications for vaccine adoption.

What happened: - The Business Research Company published a Heplisav-B market report covering market size, trends and a global forecast for 2026-2035. - The report says the market is drawing attention as healthcare systems try to raise adult immunization rates and reduce hepatitis B infections. - The analysis highlights North America as the largest market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Heplisav-B is a recombinant vaccine for adults 18 and older that helps protect against hepatitis B. - The vaccine uses hepatitis B surface antigen, or HBsAg, with adjuvant 1018 to strengthen the immune response. - Heplisav-B is given as a two-dose series within one month. - The vaccine is described as offering improved seroprotection and more convenience than traditional three-dose hepatitis B vaccines. - The report points to healthcare workers, people with chronic liver conditions and people with diabetes as key high-risk groups. - The market’s historical growth has been shaped by low adherence to three-dose schedules, more adults affected by hepatitis B, early use by healthcare professionals, demand for better efficacy and rising awareness of adult immunization. - Future growth drivers cited in the report include adult vaccination mandates, greater focus on patients with diabetes and liver disease, wider acceptance by integrated delivery networks, employer-sponsored vaccination and preventive healthcare initiatives. - Key trends include two-dose adult hepatitis B regimens, preference for high-seroprotection vaccines, higher vaccination rates among high-risk adults, more convenient schedules and workplace and occupational vaccination programs. - The report says increasing hepatitis B infections worldwide is a primary driver of market growth. - Hepatitis B can lead to acute and chronic disease, cirrhosis and liver cancer. - The report links higher hepatitis B prevalence to low vaccination coverage, high transmission rates in vulnerable groups, limited public awareness and gaps in healthcare access. - The report cites CDC data from April 2025 showing 2,214 new acute hepatitis B cases and 1,769 hepatitis B-related deaths in the U.S. in 2023. - The report also cites UK National Health Service data from June 2024 showing 3,615,330 people registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in the prior year. - The report says people with chronic diseases, especially those with weakened immune systems, may benefit from Heplisav-B’s stronger and longer-lasting immune response. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The report includes a free sample download and a full report link: Download the free sample and View the full report.

Between the lines: - The market thesis rests on a simple shift: faster, easier adult vaccination may help overcome a long-standing weakness in hepatitis B prevention. - Chronic disease prevalence broadens the addressable market because more adults are likely to be considered for vaccination in clinical and workplace settings. - Regional growth expectations suggest mature markets are already substantial, while faster adoption may come from markets still expanding vaccination infrastructure.

What's next: - The report expects growth to continue through 2035 as vaccination mandates, employer programs and preventive care spending expand. - Broader use among diabetes and liver disease patients could become an important demand source if adult vaccination guidance keeps widening. - The company’s forecast points to continued innovation in scheduling, access and program design around adult hepatitis B immunization.

The bottom line: - Heplisav-B’s growth case is tied to a durable public health need: simpler adult hepatitis B vaccination that can improve uptake and protection.